FDA re­jects cit­i­zen pe­ti­tion claim­ing Cas­sa­va ma­nip­u­lat­ed da­ta, but the biotech's woes are not over

4 years ago
FDA+

With sotro­vimab in the bal­ance, Bio­gen vet re­unites with George Scan­gos at Vir; First woman to chair PhRMA has more ...

4 years ago
Peer Review

No­vavax says its vac­cine is 80% ef­fec­tive in teens, but man­u­fac­tur­ing ques­tions con­tin­ue to cloud fu­ture

4 years ago
R&D
Coronavirus

FDA ad­vi­sors rec­om­mend against ap­prov­ing Eli Lil­ly’s PD-1, cast­ing shad­ow over fu­ture of Chi­na-made can­cer drugs

4 years ago
FDA+

Bio­gen slams cov­er­age pro­pos­al for amy­loid-tar­get­ed Alzheimer's drugs in 31-page com­ment

4 years ago
Pharma

Seagen's stock plunges af­ter re­veal­ing a dis­ap­point­ing out­look for one of its core can­cer drugs

4 years ago
Pharma

Con­gress' be­he­moth COM­PETES Act packs in pan­dem­ic pro­vi­sions for man­u­fac­tur­ers

4 years ago
Pharma
Manufacturing

Sanofi and Re­gen­eron eye younger pa­tients for Dupix­ent amid ris­ing tide of ri­vals in atopic der­mati­tis

4 years ago
Pharma
FDA+

Su­per Bowl be­yond the big brands: Bio­phar­mas get cre­ative around 'the Game'

4 years ago
Pharma
Marketing

Af­ter a con­tentious lead-up, Rob Califf like­ly to be con­firmed as FDA com­mis­sion­er next week

4 years ago
R&D

Con­struc­tion be­gins on Gen­Scrip­t's new Sin­ga­pore site; Mass­a­chu­setts CMO speeds time to mar­ket with new ca­pa­bil­i­ties

4 years ago
Manufacturing

Covid-19 roundup: Man­u­fac­tur­ers strug­gle to keep up with test de­mand; AGC inks deal for Pfiz­er's Omi­cron shot pDNA

4 years ago
Manufacturing

Cell ther­a­py pi­o­neer Mark Frohlich takes the helm at tiny In­dap­ta as a suite of big-name back­ers jump aboard

4 years ago
People
Financing

An­oth­er year, an­oth­er $9M in BAR­DA fund­ing for Medi­Wound; Af­ter PhI­II re­sults, Scynex­is will sub­mit NDA for oral ...

4 years ago
News Briefing

Rob Califf pledges 'high pri­or­i­ty' ac­cel­er­at­ed ap­proval re­forms as Sen­ate Fi­nance chair backs his nom­i­na­tion at FDA

4 years ago
FDA+

Pas­cal So­ri­ot: As­traZeneca 'on track' to hit big $40B goal, cap­ping years-long turn­around cam­paign

4 years ago
Pharma

A small Seat­tle biotech wants to take on Glax­o­SmithK­line's emerg­ing Shin­grix block­buster. RA Cap­i­tal is on board

4 years ago
Financing
Startups

The 2022 top 100 bio­phar­ma in­vestors: A look back on boom times

4 years ago
Financing
Deals

At­las-backed neu­rol­o­gy play­er Arku­da reemerges from the grind­stone with a lead pro­gran­ulin drug ap­proach­ing the ...

4 years ago
R&D

March­ing in again? Lat­est Xtan­di pe­ti­tion rais­es ques­tions on if NIH has changed its tune

4 years ago
Pharma

Covid-19 roundup: New preprint sug­gests Omi­cron sub-vari­ant can evade Vir an­ti­body; BioN­Tech-backed non­prof­it ...

4 years ago
Coronavirus

As­traZeneca picks win­ner in in­haled JAK 'bake-of­f' while sweep­ing Alex­ion drug out

4 years ago
R&D

In fi­nal analy­sis, J&J's un­der­dog vac­cine of­fers on­ly 52.9% pro­tec­tion against Covid-19

4 years ago
R&D
Coronavirus

With Paz­dur prepar­ing to low­er the boom on its PD-1, Eli Lil­ly spells out the deep dis­count on of­fer

4 years ago
Pharma
First page Previous page 576577578579580581582 Next page Last page
A service from the Financial Times